Evidence map›Paper›PMID 32824412›Full record

ArticleInternational journal of molecular sciences2020

Metastasis Suppressor NME1 Modulates Choice of Double-Strand Break Repair Pathways in Melanoma Cells by Enhancing Alternative NHEJ while Inhibiting NHEJ and HR.

Gemma Puts, Stuart Jarrett, Mary Leonard, Nicolette Matsangos, Devin Snyder, Ying Wang, Richard Vincent, Benjamin Portney, Rachel Abbotts, Lena McLaughlin and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Histidine Phosphorylation: Protein Kinases and Phosphatases.International journal of molecular sciences · 2024
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Gemma PutsDepartment of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
Stuart JarrettDepartment of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, KY 40536, USA.
Mary LeonardDepartment of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
Nicolette MatsangosDepartment of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
Devin SnyderDepartment of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.ORCID 0000-0001-8528-7538
Ying WangDepartment of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
Richard VincentDepartment of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
Benjamin PortneyDepartment of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
Rachel AbbottsDepartment of Radiation Oncology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
Lena McLaughlinDepartment of Radiation Oncology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.ORCID 0000-0002-5831-0381
Michal ZalzmanDepartment of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
Feyruz RassoolDepartment of Radiation Oncology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
David KaetzelDepartment of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.ORCID 0000-0003-2761-8970
University of Maryland, Baltimore · USUniversity of Kentucky · US

Funding

EXPAND PARTICIPATION BY MINORITIES IN BIOMEDICAL SCIENCER25GM055036 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · PI SUMMERS, MICHAEL FINLEY · 1996 to 2021
$16.9M
Training Grant in Cancer BiologyT32CA154274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Toni M Antalis, CURT I CIVIN · 2011 to 2026
$6.8M
Suppression of Melanoma Initiation and Progression by NM23-H1R01CA159871 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI KAETZEL, DAVID M · 2012 to 2016
$2.2M
NM23 PROTEINS AND MECHANISMS OF PDGF A CHAIN SILENCINGR01CA083237 · NCI · UNIVERSITY OF KENTUCKY · PI KAETZEL, DAVID M · 1999 to 2010
$1.9M
Enhancing the potency of aged adult stem cells for tissue reconstructionR01AR070819 · NIAMS · UNIVERSITY OF MARYLAND BALTIMORE · PI ZALZMAN, MICHAL · 2017 to 2021
$1.7M
NCI NIH HHS R01 CA159871NCI NIH HHS R01 CA159871-S1NCI NIH HHS R01 CA83237NCI NIH HHS T32 CA154274NIAMS NIH HHS R01 AR070819NIGMS NIH HHS R25 GM055036
6 · The paper itself

Abstract

Reduced NME1 expression in melanoma cell lines, mouse models of melanoma, and melanoma specimens in human patients is associated with increased metastatic activity. Herein, we investigate the role of NME1 in repair of double-stranded breaks (DSBs) and choice of double-strand break repair (DSBR) pathways in melanoma cells. Using chromatin immunoprecipitation, NME1 was shown to be recruited rapidly and directly to DSBs generated by the homing endonuclease I-PpoI. NME1 was recruited to DSBs within 30 min, in concert with recruitment of ataxia-telangiectasia mutated (ATM) protein, an early step in DSBR complex formation, as well as loss of histone 2B. NME1 was detected up to 5 kb from the break site after DSB induction, suggesting a role in extending chromatin reorganization away from the repair site. shRNA-mediated silencing of NME1 expression led to increases in the homologous recombination (HR) and non-homologous end-joining (NHEJ) pathways of double-strand break repair (DSBR), and reduction in the low fidelity, alternative-NHEJ (A-NHEJ) pathway. These findings suggest low expression of NME1 drives DSBR towards higher fidelity pathways, conferring enhanced genomic stability necessary for rapid and error-free proliferation in invasive and metastatic cells. The novel mechanism highlighted in the current study appears likely to impact metastatic potential and therapy-resistance in advanced melanoma and other cancers.

Indexed as

Recombinational DNA RepairAtaxia Telangiectasia Mutated ProteinsCell Line, TumorDNA Breaks, Double-StrandedDNA End-Joining RepairEndodeoxyribonucleasesGenomic InstabilityHistonesHumansMelanomaNM23 Nucleoside Diphosphate KinasesAtaxia Telangiectasia Mutated ProteinsATM protein, humanEndodeoxyribonucleasesHistonesI-Ppo endonucleaseNM23 Nucleoside Diphosphate KinasesNME1 protein, humancancerDNA double strand break repairDNA repairhoming endonucleasehomologous recombinationmelanomametastasisnon-homologous end-joining

Identifiers

PMID32824412
PMCPMC7460576
OpenAlexW3049638331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.